<html xmlns="http://www.w3.org/1999/xhtml"><head>
        <meta http-equiv="Content-Type" content="text/html; charset=utf-8">
        <meta name="viewport" content="width=device-width, height=device-height, initial-scale=0.5, minimum-scale=0.5, user-scalable=yes, maximum-scale=2.0, target-densitydpi=device-dpi" />
				<meta name="robots" content="all"/>
        <meta name="description" content="description">
        <meta name="keywords" content="">
        <title>Page 371 - MIMS April 2020 E4</title>
<style type="text/css">
<!--
body {
	margin-left: 0px;
	margin-top: 0px;
	margin-right: 0px;
	margin-bottom: 0px;
}
  
#container {margin:50px auto;padding:0px;width:910px;}
#left-button{ width:90px; height:100%;float:left }
#middle{ width:730px; margin:0px; float: left;}
#right-button{ width:90px; float:left;}
html, body, div, ul, li, dl, dt, dd, h1, h2, h3, h4, h5, h6, form, input, dd,select, button, textarea, iframe, table, th, td { margin: 0; padding: 0; }
img { border: 0 none; displayblock}
span,ul,li,image{ padding:0px; margin:0px; list-style:none;}
#top-title{ width:714px; margin-bottom:10px; float:left; padding:0px 8px}
#top-title2{ width:320px;  float:right;}
#content{ width: 730px; float:left;float:left;word-wrap: break-word;}
#content-top{ width:730px; background-image:url(images/top_bg.jpg); height:56px; background-repeat:no-repeat; float:left;}
#content-top1{ width:70%; padding:16px 0px 0px 30px; font-family:Arial, Helvetica, sans-serif; font-size:24px; color:#636363;float:left;}
#content-top2{ width:60px; float:right; padding:25px 30px 0px 0px;font-family:Arial, Helvetica, sans-serif; font-size:11px; color:#2f2f2f; font-weight:bold; text-align:right}
#content-middle{ width:730px; background-image:url(images/middle_bg.jpg); background-repeat:repeat-y;float:left;}
#content-middle1{ width:475px; padding:25px 0px 25px 35px; font-family:Arial, Helvetica, sans-serif; font-size:12px; color:#636363; line-height:150%;float:left;}
#content-middle2{  padding:7px; float:right; margin:25px 35px 0px 0px; border:solid 1px #c8c8c9; background-color:#FFF; text-align:center}
#content-bottom{ width:730px; background-image:url(images/bottom_bg.jpg); background-repeat:no-repeat; height:58px;float:left;}
#content-bottom2{ width:110px; height:42px; margin:0px auto; padding-top:4px;}
#input{ width:58px; height:20px; background-color:#FFF; border:solid 1px #dfdfe0; color:#636363; text-align:center; font-size:11px;}
.font1{ font-family:Arial, Helvetica, sans-serif; font-size:10px; color:#2f2f2f;}
.font1 a:link{
	text-decoration: none;
    color:#2f2f2f;

}
.font1 a:visited{
	text-decoration: none;
    color:#2f2f2f;
	
}
.font1 a:hover{
	color: #2f2f2f;
	text-decoration: underline;

}



.text-container {
padding: 20px;
color: #333;
margin-top: 24px;
line-height: 22px;
border-top-left-radius: 3px;
border-top-right-radius: 3px;
}

.use-as-video {
float: right;
padding-left: 20px;
}
.cc-float-fix:before, .cc-float-fix:after {
content: "";
line-height: 0;
height: 0;
width: 0;
display: block;
visibility: hidden;
}
.use-as-video-img {
cursor: pointer;
position: relative;
width: 320px;
height: 180px;
}
.use-as-video-title {
font-size: 15px;
font-weight: bold;
color: #000000;
padding-bottom: 5px;
}
-->
</style>
<script type="text/javascript">
<!--
function MM_preloadImages() { //v3.0
  var d=document; if(d.images){ if(!d.MM_p) d.MM_p=new Array();
    var i,j=d.MM_p.length,a=MM_preloadImages.arguments; for(i=0; i<a.length; i++)
    if (a[i].indexOf("#")!=0){ d.MM_p[j]=new Image; d.MM_p[j++].src=a[i];}}
}

function MM_swapImgRestore() { //v3.0
  var i,x,a=document.MM_sr; for(i=0;a&&i<a.length&&(x=a[i])&&x.oSrc;i++) x.src=x.oSrc;
}

function MM_findObj(n, d) { //v4.01
  var p,i,x;  if(!d) d=document; if((p=n.indexOf("?"))>0&&parent.frames.length) {
    d=parent.frames[n.substring(p+1)].document; n=n.substring(0,p);}
  if(!(x=d[n])&&d.all) x=d.all[n]; for (i=0;!x&&i<d.forms.length;i++) x=d.forms[i][n];
  for(i=0;!x&&d.layers&&i<d.layers.length;i++) x=MM_findObj(n,d.layers[i].document);
  if(!x && d.getElementById) x=d.getElementById(n); return x;
}

function MM_swapImage() { //v3.0
  var i,j=0,x,a=MM_swapImage.arguments; document.MM_sr=new Array; for(i=0;i<(a.length-2);i+=3)
   if ((x=MM_findObj(a[i]))!=null){document.MM_sr[j++]=x; if(!x.oSrc) x.oSrc=x.src; x.src=a[i+2];}
}
//-->
</script>
</head>

<body onload="MM_preloadImages('images/next2.png','images/previous2.png')">
<div id="container">
<div id="left-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page370.html"><img src="images/previous_big.png" width="90" height="80" /></a></p>
</div>
<div id="middle">
  <div id="top-title"><span class="font1">Basic HTML Version</span>
    <div id="top-title2">
      <table width="100%" border="0" align="right" cellpadding="0" cellspacing="0">
        <tr>
        	<td width="66%"> </td>
          <td width="35%" style="display:none" align="right"><img src="images/content.png" width="19" height="16" /></td>
          <td width="31%" style="display:none" class="font1"><a href="">Table of Contents</a></td>
          <td width="6%"><img src="images/view.png" width="19" height="16" /></td>
          <td width="28%" class="font1"><a href="../../MIMS April 2020 E4.html#p=371">View Full Version</a></td>
        </tr>
      </table>
    </div>
  </div>
  <div id="content">
     <div id="content-top">
        <div id="content-top1">Page 371 - MIMS April 2020 E4</div>
        <div id="content-top2">P. 371</div>
     </div>
     <div id="content-middle">
     	
     	  <div class="text-container">
    <div class="use-as-video cc-float-fix">
      <a style="text-decoration: none;" href="../../MIMS April 2020 E4.html#p=371"><img src="../thumb/371.jpg" /></a>
    </div>

    <p class="use-as-video-title"></p>
    <pre style="white-space:pre-line"><code>334 / 2020-04                                                                 Biologicals - 26
   rosp./VII nerve disords. (hemifac. spasm) in pts.12 yrs.& older, reduct.  exceed recomm.dos./freq., incr. system.eff.risk in known/unrecogn.  Indications: Act.hepatit.B immunisat.
   of signs & sympts.of cervic.dyston. (spasmodic torticollis) in adults.  neuromusc. disords., effs.beyond loc.inj.site observ.incl.diff. breath./  (S2) INJ. U/30.1/186.
   Bladder disords: Idiopath.overact.bladd.with sympts. of urin.incont./  swallowing & resp.depress., signif. neurologic. debil./dysphag./rec.  Adult: 20 µg Hepatitis B surface antigen/1 ml
   urg.& urin.freq.in adult fem. pts. who respon.inadeq./intoler.to anti-  aspirat.pneum. hist./ lung dis., inj.in proxim.to lung & partic.the apices   700210-001: 1 vial, R135,59
   cholinerg. meds, urin.incont.due to neurogen.detrus. overactiv. caus.  due to poss.pneumothorax, pre-exist.CV dis., vir.dis.transmiss.poss.  700210-002: 10 vials, R1 355,94
   by spin.cord inj./MS in adults willing & able to perf.clean intermitt.  due to pres.of small amnts. of album.deriv.from human bld., inj.site   (S2) INJ. W/30.1/35
   self-catheterisat. if reqd.  inflammat., inj.near vunerable anatom.struct., ser. adv.events incl.  Paed: 10 µg Hepatitis B surface antigen /0,5 ml
   Skin and skin appendage disorders: Persist. sev. prim.hyperhi-  fatal.report.in pts.inj.direct.into saliv. glands/oro-ling.-pharyng. reg./  700356-001: 1 vial, R98,08
   dros.of axill.which interf.with dly. liv. & resist.to topic.treatm., mod.  oesophag.& stomach., improvem.in range of joint mot.affect.by fix.   Dosage: Admin.IMI in deltoid reg.& anterolat. thigh for infts./neo-
   to sev.glabellar lines assoc.with corrugat.&/procerus musc.activ.in   contract.not likely, pts.to seek immed.med.care if swallow., speech   nates., exceptional.vacc.may be admin.SC in thrombocytopaen./
   pts.less than/equal to 65 yrs., mod.to sev.later. canth.lines (crow’s   or resp.disords.arise., autonom. dysreflex.assoc.with cystosc.poss.in   bleed.disords., HIV infect. doesn’t. contraindic. its use., do not mix
   feet lines) seen at max.smile, mod.to sev. crow’s feet lines seen at   pts. with neurogen.detrus.overactiv., due to the risk of urin. retent.  with other vacc.
   max.smile & glabellar lines seen at max.frown when treat. simultan.   only pts.willing & able to init. catheterisat. post-treatm.if req.should   Adults & childr.over 16 yrs: Dos.of 20 µg/ml.
   (S4) INJ, 27/30.4/0164       be consid. for treatm.of neurogen.detrus.overactiv., botulin. toxin   Neonates, infts.& young childr.up to & incl.15 yrs: 10 µg/0,5
   709214-001: 50 units/vial, 1 vial, R1 567,14  units not interchang.from one prod.to anoth. Strabismus: Ineffect.in   ml.at 6/10/14 wks.old. Childr. 11-15 yrs: Adult dos.of 20 µg as 2dos.
   813850-002: 100 units/vial, 1 vial, R3 134,27  chron.paralyt.strabism. except to reduc.antagon.contract.in conjunct.  sched.can be employ.if complete vaccinat.compliance can be ensur.&
   720379-001: 200 units/vial, 1 vial, R6 268,63  with surg. repair., careful test.corn.sensat.in eyes prev. operat. upon/  hepatit.B infect.risk low dur.vacc course.
   Dosage: Intraderm./intradetrus./IM admin. Use within 24 hrs. of   avoid.inj.into lower lid to avoid ectrop/ vigor.treat.any epithel.defect.,   Primary Immunisation schedule: All subj: Immunisat. at 0,
   reconstit.& discard remain.sol. Optimum dos. lev.& no.inj.sites/  ecchymos.in soft eyelid tiss.can be minimis.by appl.gentle press. at   1 & 6 mnths.gives optim.protect. at mnth. 7 & produc.high anti-
   musc.not determin. Indiv.regimens. Optim.dos.lev.determ.by titrat.   inj.site immed.after inj., pts.at risk for angle clos.glauc., Cervic.dys-  HB anti.titres.
   For specif. dos.instruct.see product lit.  ton: Inform cervic. dyston. pts.of poss.experienc.dysphag. Overact.   Accelerat.sched. with immunisat.at 0, 1 & 2 mnths confer quick.pro-
   Contraindications: Safety & effect.in childr.und. 12 yrs.for blepha-  bladd: Men with S&S of urin.obstruct.should not be treat. Prim.hy-  tection & better pt.compliance expect.but req.booster at 12 mnths.
   rosp./strabism./hemifac.spasm & assoc.foc.dyston.not est., infect./  perhidros.of axill: Excl.potent. caus. of second.hyperhidros. Glabell.  as titr.aft. 3rd dos.low.than those obt.aft. 0, 1, 6 mnths.sched. In infts.
   inflam.of propos. inj.site/excess.weakn./atrophy of targ.musc./gen.   lines & crow’s feet lines: Pts.with inflammat.skin probl. at inj.site/  this sched.allow for simultan.admin.of hep.B with oth.childh.vaccin.
   disords.of musc.activ., amyotroph.lat.scleros./ disords. produc.periph.  mark.fac.asymm./ptosis/excess. dermatochalas./deep derm.scarr./  Subj.11-15 yrs: 20 µg vac.may be admin.accord.to a 0, 6 mnths.
   neuromusc.dysfunct., neuromusc. junct.disords., safety in pregn.&   thick sebac. skin/ inabil.to substant.lessen glabell.lines by physic.   sched., but protect.against hep.B may not be obtain.until aft.2nd
   lactat. not est., safety & effic.in prim.hyperhidros. of the axillae./  spread.them apart, avoid inj.into a bld.ves.  dos. Use this sched. only when hep.B infect.risk low dur.vacc.course
   overact. bladd.& neurogen.detrus. overact./ glabell.lines & crow’s   Drug interactions: Eff.poss.potent.by aminoglycos. /other drugs   & when complet.of 2-dose course can be assured. If both conditis.
   feet lines/upper limb spastic.assoc.with stroke not.est.in pts.und.   interf.neuromusc. transmiss.  cannot be assur.use 3-dos./ accelerat. sched.of 10 µg vacc.
   18 yrs., safety & effect.in childr.und.16 yrs.for cervic. dyston.not est.,   Subj.18+ yrs: In except.adult cases where more rapid induct.of pro-
   safety & effic.in focal spastic. assoc.with paed.cerebr.palsy not.est.  CEREZYME 400, (Sanofi) Genzyme  tect.is reqd.eg. travellers who commen.a course 1 mnth.prior to de-
   in pts. und.2 yrs., treatm.of bladd.disords.in pts.with ac.UTI/ac.urin.  Imiglucerase  part., a sched. of 3 IMI is given at 0, 7 & 21 days. Booster recomm.
   retent.who are not routin. catheteris., pts.not will./able to init.self-  Indications: Longt.enzyme replacem.ther.in adults & paed. pts.with   12 mnths. Aft.1  dos.
                                                                    st
   catheterisat. post-treatm. if reqd.  confirm.Type I Gaucher dis.result. in one or more of the follow. condits:   Booster dos: Recomm.for haemodial.& other immunocompromis.
   Side effects: Loc.musc.weakn.spread.to adjac./ dist.musc., loc.  anaem./ thrombocytopen./bone dis./ hepatomegaly or splenomegaly.  pts. Booster dos.not recomm.in healthy individ.who have receiv.
   pain, inflammat., paraesthes., hypoaesthes., tendern., swell./oed.,   (S4) POWD.FOR INJ, 36/31/0179. 40 units/ml.  full prim.vac. course.
   erythem, loc. infect., bleed.&/bruis., fev., flu, needle-relat.pain/   715587-001: 400 U/10 ml, 1 vial, R20 634,23.  Spec.dos.recommendat: Neonat.born to mothers who are
   anx. result.in vasovag.respons., overcorrect.of childh. esotrop.,   Dosage: Admin.by IV infus.over 1-2 hrs.accord.to manuf.instruct.   HBV carriers: start immunisat. at birth & follow either 0/1/2 mnths.
   death sometimes assoc.with dysphag. /pneum/other sign.debility,   Ther.by physic. knowledgeable in Gaucher dis.  or 0/1/6 mnths. sched. To incr.protect.effic.admin.hepat.B immune
   ser. hypersens. incl.anaphylax./angioed.& ser.sickn., urticar., rare.  Indiv. Init.dos: Range 2,5 U/kg bm 3x/wk.to 60 U/kg once every 2   globul.simultan.but at diff.site
   CV events incl.dysrhythm.& MI, new/recurr. seiz., musc.atrophy,   wks. The dos.regim.of 60 U/kg every 2 wks has the most avail.data.   Known/presum.expos. to HBV: Admin.1st dos. simultan.with
   myalg., loc.musc.twitch., invol.musc.contract., periph. neuropathy,   Dis. severit. dictat init.dos.& freq. Adjust dos.on indiv. basis deter-  hepatit.B immunoglob.at sep.inject. sites using the rapid immu-
   angl. clos.glauc., abdom.pain, GI disturbs., vis.disturbs., denervat.  min.by therapeut.goal achievem.as assess. by pt.clinic.manifest.eval.  nisat.sched.
   atrophy, pyrex., hypoacusis, tinnit., vertigo, fac.palsy/-paresis,   Contraindications: Hypersens.hist., safety in pregn. not est., safety   Pts.with ren.insuff.incl.pts. undergo. haemodialys. 16+ yrs:
   brach.plexopathy, dysphon., radiculopathy, syncop., hypoaesthes.,   & effic.in pts.young.than 2 yrs.not est.  Prim.immunisat.sched. is 4 dos.of 40 µg at elect.date, 1, 2 & 6
   malaise, myalg., myasth.grav., erythema multiform, prurit., der-  Side effects: Loc.reacts., hypersens.incl.cyanos. /dyspn./angioed/  mnths from date of 1st dos. Adapt sched.to maint anti-HBs anti-
   matit.psoriasisform, hyperhidros., alopec., madarosis.  flush., anaphylact.reacts., fatig., headache, dizzin., tachycard., GI   body titre ≥ 10 iu/L.
   Neurolog.disords: Foc.spastic.assoc.with paed. cerebr.  disturbs., rash, fev., chills, backache, periph.oed., pulm. hypertens.   Pts.with ren.insuffic.incl.pts.undergo. haemodialys. up to and
   palsy: Vir./ear infect., somnol., gait disturb., paraesthes., rash,   & pneumon.report.but no caus. relationship est.  incl.15 yrs. incl. neonat: Use either 0, 1, 2 & 12 mths. or 0, 1, 6 mths
   myalg., musc.weakn., extrem.pain, urin.incontin., injury, poison.&   Special precautions: Nurs.women as unknown if excret. in human   sched.of 10 µg vacc. Addition.dos.may be need.to maint anti-HBs
   procedur. complicats., fall, malaise, inj.site pain, asthen.  milk, high.hypersens.react.in pts. with detect.IgG antibodies, eval.pts.  antibody titre ≥ 10 iu/L.
   Foc.upp.limb spastic.assoc.with stroke: Depress., insomn.,   with resp. sympt. without fev.for pulm.hypertens., monit. per. for IgG   Contraindications: Sev.febr.infects., IV admin.
   hyperton., hypoaesthes., headache, paraesthes/inco-ordinat.,   antibody format.dur.1 st  treatm. yr, prev. treatm. with placenta-deriv.   Side effects: Loc.reacts., rarely fev., malaise, flu-like sympts., skin
   amnes., vertigo, orthostat.hypotens., GI disords., ecchymos., pur-  glucocerebrosidase where antibod.develop./ hypersens. sympts.  erupts., syncope, GI disturbs., CNS/ musculoskelet.syst.effs., rarely
   pura, dermatit., prurit., rash, extrem.pain, musc. weakn., arthralg.,   shown., pts.who exper. anaphylact. reacts.but success.cont.furth.  anaphylax., ser. sickn., hypotens., centr.& periph.nerv.syst. disturbs.,
   bursit., inj.site pain,/ haemorrh./ irrit, pyrex., flu-like illn., asthen,,   ther. aft.infus.rate reduct.& pre-treat.with antihistam. &/ corticoster.  arthrit., bronchosp.like sympts., vasculit., angioed., erythema multi-
   pain, malaise, periph.oed.   CERVARIX, GSK [P/S]           forme, lympadenopathy., loss of appet., myalg., arthralg., meningit.,
   Strabismus: Eyelid ptos., eye movem.disord., ocular retrobulb.  Human Papillomavirus type 16 L1 prot. 20 µg, type 18 L1 prot.20 µg,   thrombocytopaen., musc.weakn.
   haemorrh., eye penetrat., Holmes-Adie pupil, vitreous haemorrh.  3-O-desacyl-4-monophosphoryl lipid A (MPL) 50 µg, Al hydrox. hydrat.    Warnings and special precautions: Poss. unrecogn. infects.at
   Blepharospasm and hemifac.spasm: Dizzin., fac. pares./palsy,   0,5 mg Al /0,5 ml dos.  time of vaccinat.due to long incubat. period, may not prev.hepatit.B.,
                                    3+
   eyelid ptos., oed., punct.keratit., lagophthalm., dry eye, photophob.,   Indications: Prev.of persist.infect., premalign. ano-genit. (cerv., vulv.,   rep.admin. for pts.with imp.immune syst.& dialys.to obt.adeq. anti-
   eye irrit., incr. lacrimat., keratit., ectrop., diplop., entrop., vis.   vagin.& anal)les.& cervic., vulv., vag. & anal Ca (squam.-cell Ca & ad-  body conc., pregn./lact., avoid gluteal./ intraderm. admin.as result.
   disturb., blurr.vis., ulcerat.keratit., corn.epithel. defect, corneal   enocarcin.) caus.by onocogen.human papillomavirus (HPV) from 9 yrs.   immun.resp.not optim., not effect.against Hepatit.A/C/E, potent.
   perforat., ecchymos., rash/ dermatit., irrit., fac.oed.  (S2) INJ, 41/30.1/0366  apnoea risk in prem.infts., adrenal.to be readily avail.for immed. use
   Cervic.dyston: Rhinit., URTI, dizzin., hyperton., hypoaesthes., som-  710020-001: 1xsngl.dos syr., R870,06  in case of anaphylax.
   nol., headache, diplop., eyelid ptos., dyspn., dysphon., dysphag.,   Dosage: Admin.by IMI in deltoid reg.
   dry mouth, naus., musc.weakn., musculoskelet.stiffn., soren., pain,   Vaccinat. sched.dep.on age of pt. Age 9 -14 yrs. of age at time of   ERBITUX, (Biopharma Div) Merck [P/S] &
   asthen., flu-like illn., malaise, pyrex.  first inject: 2 x 0,5 ml dos. Give 2  dos. 5 - 13 mnths.aft.1  dos. If 2   nd  Cetuximab
                                              nd
                                                        st
   Bladd.disords: Overact.bladd.: UTI, bacteriur., dysur., urin.  vacc.dos. is admin. bef.the 5  mnth.aft.the 1  dos.a 3  dos. should   Indications: In combinat.with irinotecan-based chemother. for epi-
                                            th
                                                       rd
                                                   st
   retent., resid.urine vol., pollakiur., leukocytur.  always be admin. Age 15 yrs. and above: 3 x 0,5 ml dos.at 0, 1,   derm.growth fact.recept.(EGFR)-express. RAS wild type metastat.
   Urin.incontin.due to neurogen.detrus.overact.: UTI, insomn.,   6 months. If flexibil.necess. in vaccinat.sched.the 2  dos can be ad-  colorect.Ca, in first-line in combin.with contin.infus.FOLFOX, as sngl.
                                                     nd
   constip., musc.weakn., musc.spasm, urin.retent., haematur., dysur.,   min.1 - 2,5 mnths. aft.the 1  dos. & the 3  dos.5 - 12 mnths. aft. the   agent in pts.who fail.oxaliplatin-& irinotecan-based ther.& intol.to
                                                 rd
                                            st
   bladd.diverticul., fatig., gait disturb., autonom.dysreflex., fall.  1  dose. . Necess.for booster dos.not est. Sust.protect.effic.est.for   irinotecan,loc.advanc.squam. cell head & neck Ca in combinat.with
                                 st
   Skin & skin append. disords. Prim. hyperhidros. of the   up to 9,4 yrs.aft.1st dos.  radiat.ther., sngl.agent in recurr.and/or metastat.squam.cell head &
   axillae: Headache, paraesthes., hot flush., naus., hyperhidros.   Side effects: Very comm: Headache, myalg., inj. site reacts.incl.   neck Ca where chemother.fail., in combin. with platin.-based chem-
   (non-axillary sweat/), abnorm. skin odour, prurit., subcutan.nodule,   pain/redn./swell., fatig. Comm: N&V, diarrh., abdom. pain, itch./  other.for recurr.&/ metastat. squam.cell Ca of head & neck.
   alop., extrem.pain, musc.weakn., myalg., arthropathy, inj. site pain/  prurit., rash, urticar., arthralg., fev. Uncomm: URTI, lymphadenopa-  (S4) SOL.FOR INFUS, 41/30.2/0883. 5 mg/ml
   oed./haemorrh./hypersens./irrit.reacts., asthenia,   thy, dizzin, other inj.site reacts.incl. indurat./ loc. paraesthes. Rare:   715052-001: 1x20 ml vial, R3 006,41
   Glabell. lines: Infect., anx., headache, paraesthes, dizzin., eyelid   Allerg.reacts.incl. anaphylact. reacts., angioed., syncope/ vasovag.   Dosage: Admin.only by physic.exper.in antineoplast. prod.with
   ptos., blepharit., eye pain, vis. disturb., naus., oral dryn., erythema,   respons. to inj., tonic-clon. movem.  clos.monit.dur.infus.& 1 hr. post infus.in facilit.equip.with resuscitat.
   skin tightn., oed. (fac., eyelid, periorbit.), photosens. react., prurit.,   Warnings and special precautions: Not substit. for reg. screen./  equipm. Admin.premed.of an antihistam.& a corticoster.at least 1 hr
                                                                  st
   dry skin, localis.musc.weakn., musc. twitch., fac.pain, inj.site oed./  HPV expos.& sex. transmitt. dis.precaut., expect.respons.poss.not obt.   prior to 1  & all subseq.infus. Admin. once a wk. Admin.init.dos.slow.
   pain/irrit., ecchymos.,,flu syndrome, asthen., fev.  aft.vaccinat.of immunosuppress.pts.eg.HIV infect. pts., thrombocy-  not exceed. 5 mg/min.over 120 mins. Infus.subseq.wkly.dos. over
   Crow’s feet lines: Eyelid oed., inject.site haemorrh., haematoma,   topen./any coagulat.disords. as bleed. poss., have appropr.medic.  recomm.infus.period of 60 mins. Do not exceed infus.rate 10 mg/
   pain, paraesthes.            treatm.avail.in event of rare anaphylact.reacts., ensure proced.in   min. Discont.if react.occurs.within 1  15 mins.of infus.
                                                                             st
   Crow’s feet lines & glabell. lines: Inj. site haemat./ haemorrh./ pain  place to avoid injury from faint.as syncope.poss., admin. other con-  All indicat: Init: 400 mg/m body surf.area IV via separate in-line
                                                                          2
   Warnings and special precautions: S/E poss.despite ther.prev.  com.inj.vacc.at diff.inj.sites, not for IV/intraderm.admin., not to be mix.  filtrat.with infus.pump/grav.drip/ syringe pump X120 mins. Subseq.
   well tolerat., S/E durat.may be sev.mnths./long, sedent.pts.to slow.&   with other meds., pregn., use in lactat.when benef.outweighs poss.   wkly.dos: 250 mg/m each with infus.per:60 mins.
                                                                      2
   careful. resume activ., exaggerat.musc.weakn.poss., old.& debilitat.   risk, review medic.hist./clinic.exam.bef. admin., postpone vaccinat.  Colorect.Ca: In combination with chemother./as sngl.agent where
   pts., safe & effect.use depend.on proper storage/ correct dose/re-  in ac.sev.febrile illn., no data avail.on SC admin., protect.immune re-  oxaliplatin & irinotecan bas.ther. fail./irinotecan intol. Evid. of wild-
   constit.& admin.techniq., discontin. & instit.appropr.ther.in case of   spons. not elicit.in all vacc., does not prev.HPV-relat.les. progress./  type RAS (KRAS & NRAS) status reqd.prior to 1  cetuximab infus.
                                                                                  st
   hypersens. reacts., physic.to understand relev. neuromusc.anatom./al-  prov. protect.against all oncogen.HPV types., may be giv.with dTpa/  Determ.mutat.status using valid.test method for KRAS & NRAS (ex-
   terat.anatomy from prior surg.& std.electromyograph.techniq., clinic.   IPV/dTpa-IPV, HepA, rDNA HepB/combin.HepA-HepB vacc.  ons 2,3 & 4) mutat.by exper.lab.
   fluctat.from rep.use, excess.weakn./atrophy in target. musc., reduc.  Ref.to chemotherapeut.agents prod.lit.for concom. dos. Admin.
   effectiven.with antibod.pres., safety & effic.in pts.over 65 yrs.not est.,   ENGERIX-B, GSK [P/S]  not earlier than 1 hr.aft.end of Erbitux infus. Contin.Erbitux unt.un-
   physic.to be adeq.train.& have access.to adeq.resuscit. facilit., do not   Recombinant DNA hepatit.B vacc.  derly.dis.progress.</code></pre>
     	</div>
    
     </div>
     <div id="content-bottom">
       <div id="content-bottom2">
         <table width="110" border="0" cellspacing="0" cellpadding="0">
           <tr>
             <td width="22%" height="44"><a href="page370.html"><img src="images/previous.png" width="26" height="19" id="Image2" onmouseover="MM_swapImage('Image2','','images/previous2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
             <td width="43%">
             	&nbsp;&nbsp;&nbsp;<a href="page366.html">366</a>&nbsp;&nbsp;&nbsp;<a href="page367.html">367</a>&nbsp;&nbsp;&nbsp;<a href="page368.html">368</a>&nbsp;&nbsp;&nbsp;<a href="page369.html">369</a>&nbsp;&nbsp;&nbsp;<a href="page370.html">370</a>&nbsp;&nbsp;&nbsp;<a href="page371.html">371</a>&nbsp;&nbsp;&nbsp;<a href="page372.html">372</a>&nbsp;&nbsp;&nbsp;<a href="page373.html">373</a>&nbsp;&nbsp;&nbsp;<a href="page374.html">374</a>&nbsp;&nbsp;&nbsp;<a href="page375.html">375</a>&nbsp;&nbsp;&nbsp;<a href="page376.html">376</a>
             </td>
             <td width="35%"><a href="page372.html"><img src="images/next.png" width="26" height="19" id="Image1" onmouseover="MM_swapImage('Image1','','images/next2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
           </tr>
         </table>
       </div>
     </div>
  </div>
</div>
<div id="right-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page372.html"><img src="images/next_big.png" width="90" height="80" /></a></p>
</div>


</div>

</body>
</html>
